GAVI needs to offer lower vaccine prices to humanitarian actors
Official estimates place the number of babies not fully vaccinated in 2011 at 22.4 million, which is equivalent to one in five children born each year. Through its work in unstable contexts and regions that persistently lag behind on vaccination, MSF is often close to children who are under- or unvaccinated.
“We need to be able to act quickly and provide life-saving vaccines to vulnerable children as these opportunities arise,” said Florence Fermon, head of MSF’s Vaccination Working Group. “We can’t afford unnecessary delays trying to get hold of vaccines through lengthy negotiations.”
MSF has tried in several places to obtain newer vaccines for use in its projects. In late 2010 and early 2011, it took MSF more than four months of negotiations with the Ministry of Health and pharmaceutical company GlaxoSmithKline to obtain the pneumococcal vaccine for use in its projects in
MSF has unsuccessfully tried to obtain the pneumococcal vaccine from Pfizer at the GAVI price.
At the core of the problem is that GAVI brokers deals with pharmaceutical companies that exclude other actors from accessing the prices. These deals often involve prices for vaccines that are still high and unaffordable for countries in the long run.
“We need access to vaccines when we need them, where we need them and at an affordable price,” said Dr. Manica Balasegaram, Executive Director of MSF’s Access Campaign. “It’s time for GAVI to wake up and recognise that other actors vaccinating on the ground need fast and regular access to life-saving vaccines at the lowest-possible prices.”